Exploring how Denmark and Norway navigate the 'resource curse' by diversifying wealth, and the cautionary tales from Nokia's rise and fall in Finland. The chapter also examines the competitive challenges Novo Nordisk faces from Eli Lilly in the pharmaceutical market.